Xeljanz & Opzelura – What the Flip is a JAK Inhibitor? Artwork

Druggist For The People

Four score and seven minutes ago (about an hour and a half) your physician brought forth, upon her desk, a new prescription, conceived in best medical practice, and dedicated to the proposition that all generics are created equal. Now we are engaged in a great civilian war, testing whether that medication, or any medication so conceived, and so dedicated, can help us long endure. And maybe we can feel good at the same time. For forty years as a pharmacist, I've been building bridges - from the doctor to those in need of important drug information - you. With respect for the listener, and from the perspective that it is better to apply a recommended course of therapy than it is to comply with an ordered course, the goal here is not to provide specific answers about your drug therapy, but rather to help you generate the questions that will that will empower you in this. Toward that end, there will be weekly podcasts, very often with guests who will be "the people".

All Episodes

Druggist For The People

Xeljanz & Opzelura – What the Flip is a JAK Inhibitor?

April 16, 2024 • Donald Schoeff R.Ph.

Send us a text

Summary: The drug ads float images of happy people across the room, with a voiceover discussing the mechanism of actions of the drug (JAK inhibitor) along with an undercurrent of warnings and side effects of the drug. One of the newer drug groups are these JAK inhibitors, an oral form of targeted immunotherapy. This episode attempts to explain this drug group, and also discusses to whom exactly the drug companies are directing their ads.

Topics:

· Drug Ads 01:20

· Opzelura 02:00

· Targeted Immunotherapy 02:45

· Monoclonal Antibodies (MABs) 03:15

· JAK Inhibitors – small molecules 03:45

· Risk-Benefit Discussion 14:30

· Black Box Warnings 15:30

· Monitor and Journal 19:00

· Participate!

Questions and comments to druggistforthepeople@gmail.com

People on this episode

Donald J. Schoeff, R.Ph.

Host